MTOR and Adenoma sebaceum: The International TSC Consensus Group does not recommend systemic therapy for the exclusive treatment of facial angiofibroma due to the risk of systemic side effects and has found insufficient evidence regarding an additive effect of topical mTOR inhibitors for facial angiofibroma as an adjunct to systemic therapy [27].